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Abstract: Increasing biological applications of fullerenyl amino acids and their derivatives 
encouraged us to synthesise [60]fullerenyldihydropyrrole peptides, prepared from the coupling 
of mono and bis [60]fullerenyldihydropyrrole carboxylic acids 4, 5 and 41 with presynthesised 
peptides 13, 16, 24, 28, 29 and 46. The resulting hydrophobic scaffolded di and tetra cationic 
derivatives were tested against Staphylococcus aureus NCTC 6571 and Escherichia coli 




There are significant health care issues posed by multidrug resistant human pathogenic 
bacteria.[1,2] Of particular concern is the emergence of Gram-positive bacteria, e.g. 
Staphylococcus aureus and Enterococcus faecium, resistant to the glycopeptide antibiotic, 
vancomycin.[3-5] Recently, there emerged a new variation to the peptide class of antibiotics, 
exemplified by 1 (Figure 1).[6] These dicationic binaphthyl-templated linear peptides possess 
some similarity to structural aspects of vancomycin and could potentially act in a similar way 
but have added flexibility for interacting strongly with the changed peptido-glycan cell wall 
moiety[7] in vancomycin-resistant bacteria.[8] Also, there is significant antimicrobial activity in 
some biaryl-based cyclic β–hairpin cationic peptidomimetics.[9] While medicinal chemistry 
investigations of 1 as antibacterial agents made significant progress with the evolution of the 
amino acids required[10] and the better termini,[6] early investigations into alternatives to the 
binaphthyl unit were restricted to macrocycles anchored by hydrophobic scaffolds based on 
3,3′-amino acid linked 1,1′-binaphthyls,[11] carbazoles,[12-13] indoles,[14] benzenes[15] and 
benzo[b]thiophene.[16] The outcomes of these studies indicated that changing from the 
binaphthyl hydrophobic scaffold to smaller units severely decreased activity to the point of 
complete inactivity. Therefore, the hydrophobic bulk of the scaffold is critical in the structure-
activity relationships of this class of compounds. Considering that all of these approaches 
investigated reducing the size of the hydrophobic anchoring unit, we thought that alternative 
hydrophobic units could match the space occupied by the binaphthyl unit. We have had 
considerable experience in the synthesis and use of amino acid substituted [60]fullerenes[17] 
and given the diameter of [60]fullerenes is 6.8 Å and the distance from distal points of the 
binaphthyl moiety is 8.3 Å, we considered the possibility of replacing the binaphthyl unit with a 
[60]fullerene. The synthesis of these molecules and their antibacterial activities are reported 
here. 
The fullerene moiety is becoming increasingly prominate in biological applications[18], both as a 
‘substituent‘ but also as templates for the construction of macromolecules. Examples of mixed 
fullerenyl macrocycles include glycoconjugates[19] and fullerenyl amino acids[20] – it is the later 
which is of significance to this project. To date, such systems have been the focus of a variety 
of materials and medicinal chemistry projects and thus far take the form of fullerene pendents 
to amino acid oligomers with linkers, fullerenyl-capped amino acids and the most prevalent, 
the incorporation of the fulleroproline moiety. In most instances, the C60 unit is an anchor, and 
not representative of a true -amino acid side chain, with linker units providing space between 
the two moieties. The fullerenoprolines provide examples closer to the incorporation of 
fullerenoamino acids in peptide chains. In our proposed target molecules, the fullerene moiety 
will be a true fullerenyl -amino acid and will be incorporated directly to the peptide chain. 
Additionally, the peptide chain will be rich in arginines and lysines, amino acids not necessarily 
prevalent with known fullerenyl peptides. However, recent examples of cationic fullerenyl 
conjugates[21] suggest that the incorporation of protonated ‘basic‘ side chains should pose no 
issues. Therefore, the combination of the hydrophobic C60 unit and the protonated basic side 
chains has the potential for interesting solubility issues, possibly beneficial for the delivery of 
bioactive molecules. 
 
Figure 1. Binaphthyl-anchored peptide antibiotic agents. 
Results and Discussion 
The target compounds contain [60]fullerene anchoring cationic peptide chains and are 
exemplified by the general structure 2 (Figure 2). Significant SAR studies have been 
established with respect to the cationic amino acid side chains. Therefore, this study focused 
on a short linker between the fullerene moiety with a peptide of variable length, but restricted 
to either n = 0 or 1. The amino acid side chains will be either Lys or Arg, or combinations 
thereof – these would be tested as the dicationic salts, either chlorides or TFA salts. We have 
previously reported that despite the multiple stereogenic elements present in the molecule, 
different diastereomers of the same molecules had little difference in their antibacterial 
activity.[6] Therefore, no ideal stereochemical combination exists, prompting us in this study to 
investigate a range of different stereochemical possibilities. The peptide chains are then 
capped with a variety of small terminal hydrophobic units – here, we targeted the ester and 
oxazole termini (R in structure 2, Figure 2). 
 
Figure 2. Structure of the target [60]fullerene based dicationic peptoids 2. 
Chemistry 
The synthesis of the target compounds began with the generation of the [60]fullerenyl amino 
acid scaffold 5, which was achieved using known chemistry to generate the acid 4. [17] 
Therefore, the reaction of commercially available tert-butyl 2-
((diphenylmethylene)amino)acetate 3 with [60]fullerene under Bingel reaction conditions 
produced a [60]fullerenyldihydropyrrole tert-butyl ester derivative in 60% yield, which was 
treated with TFA to give the fullerenyl acid 4 (90%) (Scheme 1). This acid was reacted with 
tert-butylglycinate under EDCI/HOBt or HBTU peptide coupling conditions, followed by TFA 
treatment to give the acid compound 5 (48%). This second step adds the short linker to the 
molecule in the form of a Gly unit. 
The next stage towards [60]fullerenyl-anchored peptide anti-bacterial molecules is the 
synthesis of the peptide moieties. In this approach, we wanted to make a number of 
derivatives to encompass a range of analogues without necessarily making systematic one-
step changes, but instead, encompassing a range of derivatives. Scheme 2 outlines the 
synthesis of the tripeptide (e.g. 13 and 14) and tetrapeptide (e.g. 16) moieties for linking to the 
fullerenyl hydrophobic scaffold. Therefore, the free amine 6, containing an isopentylester was 
synthesised by reported procedures,[6] and coupled with Fmoc-D-Arg-OH (R = Pmc or Pbf) to 
produce dipeptides 7 (R = Pmc) and 8 (R = Pbf) (Scheme 2). These differ only in the 
protecting group and both were made due to ease of availability of starting materials at the 
time. Subsequent Fmoc deprotection and coupling with D or L-(Boc)-Lys-OH resulted in 
tripeptides 11 and 12, which upon Fmoc deprotection and gave the free amines 13 and 14, 
respectively. The reaction of 14 with Fmoc-Gly-OH produced the tetrapeptide 15, which was 
Fmoc deprotected to yield 16. This sequence produced two tripepetides (13 and 14) and a 
tetrapeptide (16) with a terminal isopentyl ester and a free amino substituent, ready for peptide 
coupling with a fullerenyl amino acid. 
 
Scheme 1: Synthesis of the fullerenyl amino acid hydrophobic anchor: Reagents and 
conditions: (a) DBU, CBr4, toluene, 6 h, rt, C60, 60%. (b) TFA, CH2Cl2, rt, 3 h, 90%. (c) tert-
butyl glycinate, CH2Cl2, EDCI/HOBt or HBTU, rt, 5 h, 48%. 
 
The synthesis of the peptide moieties containing an oxazole terminus started with the 
synthesis of 17 by reported methods[22] (Scheme 2). This oxazole 17 then underwent a typical 
coupling with N,N'-diprotected forms of either L-Arg or D-Lys to produce 18 and 19, which 
were deprotected to the free amines 20 and 21, respectively. Reaction of these amines with 
Fmoc-D-Lys-(Boc)-OH gave 22 and 23, which were Fmoc deprotected giving 24 and 25, 
respectively - a final coupling with Fmoc-Gly-OH gave the tetrapeptides 26 and 27 and after 
Fmoc deprotection provided the free amines 28 and 29 for further coupling reactions to 
hydrophobic scaffolds. 
The protected fullerenyl peptoids 30-33 were successfully synthesised by coupling 
[60]fullerenyldihydropyrrole acid 4 with the presynthesised peptides 16, 24, 28 and 29 under 
EDCI/HOBt peptide coupling conditions (Scheme 3). In a typical example, the tetrapeptide 16 
was added dropwise to a solution of acid 4 and HOBt in CH2Cl2, which was sonicated for 15 
minutes to aid solubility. EDCI was added at the same temperature and the reaction mixture 
was stirred for four hours at room temperature. As the reaction progressed, the turbid solution 
transformed to a clear brown solution and upon workup, the first-in-class [60]fullerenyl 
anchored tetrapeptide 30 was isolated. Synthesis of compound 31 was possible by coupling 
with the oxazole terminated tripeptide 24, and the tetrapeptide version of 28, with the extra 
glycine amino acid in to the peptide chain, was responsible for producing 32. Coupling the acid 
4 with peptide 29, which contained two Boc protected lysines with an oxazole terminus, 
yielded 33. This reaction used CHCl3:CH2Cl2 (1:1) as a solvent due to better solubility of the 
diBoc protected lysine containing peptide whereas the synthesis of compounds 31 and 32 only 
required CH2Cl2 as the single solvent.  
Analysis of the 1H NMR of fullerenyl amino acid 34 indicated doublet of doublets centred at 
7.36 ppm and 7.47 ppm, assigned to the para and meta protons respectively of the gem 
diphenyl substituents of the proline moiety, with the corresponding ortho protons assigned to 
the doublet at 8.03 ppm. The methylene of the glycine unit was assigned to the broad singlet 
at 3.26 ppm. Analysis of the HR ESI MS indicated a peak at m/z 1436.3822, assigned to the 
mono cationic species of 34, C97H49N9O6. 
An additional antibiotic target molecule to consider is the [60]fullerene that is doubly 
substituted with peptides chains. Therefore, the previously unknown diacid 41 was 
synthesised from the reported bis-adduct 40,[17a] by using trimethyltin hydroxide[23] at 80 °C or 
borontribromide at -10 °C to room temperature - the former conditions resulted in a better yield 
of 65% compared to the latter of 50% (Scheme 4). As expected, attempts to synthesise 
[60]fullerene bis peptoid 42 using diacid 41 and peptide 13 under the standard coupling 
conditions used previously in this study failed, due to poor solubility. No progress in the 
coupling reaction was observed even after longer reaction times and an increase in reaction 
temperature to 60 °C. Therefore, a change in solvent to a 1:2 ratio of pyridine/chloroform was 
used generating a successful outcome with a 50% reaction yield of 42 (Scheme 4). 
Unfortunately, attempted deprotection of 42 with TFA gave an insoluble product that could not 
be characterised. Analysis of the 1H NMR spectra of 42 showed a singlet (18H) at 1.28 ppm, 
assigned to the two Boc groups attached to the lysine side chains. The presence of a single 
peak for these two groups indicates that both peptide side chains are in an equivalent 
environment and this is consistent with the expected Cs symmetry of the trans-4 disubstituted 
[60]-fullerene.[24] The presence of 29 sp2 resonances confirms this symmetry. Analysis of the 
HR ESI MS indicated a peak at m/z 2884.1675, assigned to the sodiated species of 42, C-
174H164N16O20S2Na. 
 
Scheme 2: Reagents and conditions: (a) Fmoc-D-arg-(Pmc/Pbf)-OH, Fmoc-L-arg-(Pmc)-OH 
or Fmoc-D-lys(Boc)-OH, EDCI, HOBt, CH2Cl2, rt, 4 h, 66% for 7, 75% for 8, 65% for 18 and 
68% for 19; (b) piperidine, CH3CN, rt, 4 h, 77-88%; (c) Fmoc-D or L-Lys-(Boc)-OH, EDCI, 
HOBt, CH2Cl2, rt, 4 h, 79% for 11, 80% for 12, 86% for 22 and 72% for 23; (d) Same 
conditions as (b) 88% for 13, 77% for 14, 84% for 24, and 85% for 25; (e) Fmoc-Gly-OH, EDCI, 
HOBt, CH2Cl2, rt, 4 h, 75% for 15, 71% for 26 and 82% for 27; (f) Same conditions as (b) 80% 
for 16, 88% for 28, and 86% for 29. 
 
Scheme 3: Synthesis of C60 fullerenyl anchored amino acid oxazoles and isopentyl esters. 
Reagents and conditions: (a) EDCI, HOBt, CH2Cl2, rt, 4 h; (b) TFA/ CH2Cl2 +(1:1), rt, 16 h; 
(c) 1 M HCl.Et2O, 0-rt 0.5 h. 
 
Scheme 4: Reagents and conditions: (a) (tert-butoxycarbonyl)glycine, THF, DMAP, CH2Cl2, 
rt, 40 h, 80%. (b) TFA, CH2Cl2, rt, 3 h, 90%. (c) CH2Cl2, diphenylmethanimine, 24 h, rt, 75%. 
(d) DBU, CBr4, rt, Toluene, C60, 6 h, 45%. (e) (CH3)3SnOH, DCE, 80 
oC, 24 h, 65%. (f) BBr3, 
CH2Cl2, -10 
oC - rt, 18 h, 50%. (g) pyridine/chloroform (1:2), EDCI, HOBt, 8 h, 50%.  
 
The synthesis of the fullerenyl peptide 50 was achieved using a modified route (Scheme 5). 
Initially, the dipeptide 46 was synthesised from intermediates 43 and 44 under standard 
coupling-deprotection conditions. The dipeptide 46 was then coupled to the fullerenyl amino 
acid 5 yielding 47 in a 67% yield. Subsequent deallylation followed by coupling to isopentyl-L-
leucinate gave the tetrapeptide coupled [60]fullerenyl peptide 49 in 62% yield. Final side chain 
deprotection under standard conditions followed by salt formation yielded the final product 50 















































































































Scheme 5: Reagents and conditions: (a) EDCI, HOBt, TEA, CH2Cl2, rt, 4 h, 85%; (b) TFA: 
CH2Cl2 (4:6), rt, 4 h, 90%; (c) HBTU, TEA, CH2Cl2, rt, 4 h, 67%; (d) (CH3)3SnOH, 1,2-DCE, 
80 °C, 6 h, 84%; (e) isopentyl L-leucinate hydrochloride, EDCI, HOBt, TEA, CH2Cl2, rt, 4 h, 
62%; (f) piperidine, CH3CN, rt, 4 h, 72%; (g) 1 M HCl.Et2O, 0 °C-rt, 0.5 h, 70%. 
 
To improve the solubility of the [60]fullerene based peptides for antibacterial testing, it was 
necessary to use them as dicationic salts, which were prepared using either TFA and/or 1 M 
HCl in ether. Peptides 31, 32 and 49 were made as the HCl salts 35, 36 and 50, respectively 
by treating with TFA/CH2Cl2 (1:1) to deprotect the Pmc/Pbf and N-Boc functional groups then 
after removing the solvents under reducing pressure, the residue was resuspended in a 
minimal volume of CH2Cl2 and treated with an excess amount of 1 M HCl in ether to obtain the 
targeted HCl salts. The peptides 30 and 33 were made as their TFA salts 34 and 37 by 
treating with TFA/CH2Cl2 (1:1) to deprotect the Pmc/Pbf and N-Boc groups and at the same 
time forming the TFA salts. All salts were characterised by HRMS, and additionally, 34, 35 and 
36 returned 1H NMR spectra of good quality. Unfortunately, due to limited solubility of these 




As an initial screen for biological activity, the [60]fullerenyl peptides 30-33, 42, 47 and 49 and 
the dicationic salts 34-37, and 50 were subjected to in vitro antibacterial testing. These twelve 
[60]fullerene derivatives were tested using the broth microdilution method against 
Staphylococcus aureus NCTC 6571 and Escherichia coli NCTC 10418. MICs for antibiotic 
positive controls tested simultaneously were 4 µg/mL for kanamycin and 2 µg/mL for 
chloramphenicol for E. coli and for S. aureus were 4 µg/mL for kanamycin and 1 µg/mL for 
vancomycin. Unfortunately all fullerenyl-based compounds were inactive, even at higher 




The synthesis of peptides anchored by [60]fullerenes was successful with a series of mono 
substituted and disubstituted fullerene derivatives were synthesised. Although these 
derivatives did not show any anti-bacterial activity, their synthesis has progressed the 
development of the important field of fullerenyl amino acids and peptide derivatives, in 
particular, their synthesis and isolation as peptide salts. This is highlighted by the reasonable 
solubility of the deprotected compounds in DMSO/water and the relative ease of purification of 
the protected fullerenyl peptides by column chromatography. Further, these fullerenyl amino 
acids have a more rigid, and thus more defined, tethered structure than most other fullerenyl 
peptides reported, which traditionally employ a flexible fullerene-peptide linker. These more 




1. General Synthetic Procedures 
Protocol 1: Peptide coupling 
To a solution of the acid in dichloromethane or chloroform (10 mL/0.10 mmol) at room 
temperature was added EDCI/HBTU (1.2 equiv.), HOBt (1.2 equiv.), and the amine (1 equiv.). 
If the amine was a hydrochloride salt, DIPEA (1.2 equiv.) or TEA (1.2 equiv.) was also added. 
After stirring for 3-6 h, the solvent was removed under reduced pressure, and then the 
resulting residue was subjected to silica gel column chromatography (1-4% MeOH/CH2Cl2 as 
the eluent) to afford the coupled product.  
Protocol 2: N-Fmoc deprotection 
The Fmoc-protected amine was stirred in 1 equiv. of piperidine/acetonitrile (5 mL/0.10 mmol) 
overnight at rt, unless otherwise stated. The solvent was removed under reduced pressure 
and the crude product was purified by column chromatography, using 5% MeOH/CH2Cl2 to 
yield the free amine.  
Protocol 3: N-Boc, Pbf and Pmc deprotection 
The N-Boc, Pbf or Pmc protected amine was stirred for 1 h (for Boc) or overnight (for Pbf and 
Pmc) in 1:1 CH2Cl2/TFA (6 mL/0.10 mmol) solution at rt. The solvent was removed under 
reduced pressure, and the residue was resuspended in a minimal volume of CH2Cl2. The 
solution was then treated with an excess of 1 M HCl/ether (2 mL/0.01 mmol) solution and the 
solvent evaporated. The crude product was purified by precipitation from CH2Cl2, with hexane 
and diethyl ether. 
Protocol 4: Allyl and bis-1,3-benzyl ester hydrolysis 
To a solution of the ester in 1,2-dichloroethane (10 mL/0.10 mmol) at rt was added 
Sn(CH3)3OH (4 equiv.) and the solution was heated at 80 
oC for 4 h, then 4 more equiv. of 
Sn(CH3)3OH was added at the same temperature and the reaction was continued for further 4 
h. The reaction mixture was evaporated under reduced pressure and the resulting residue was 
taken up in dichloromethane (15-20 mL). The organic layer was washed with 5% HCl (3 x 10-
15 mL), brine (3 x 10 mL) and dried over Mg2SO4 and evaporated under reduced pressure to 
yield corresponding acid. 
 
Supporting Information 
Full experimental procedures and spectral data, and copies of 1H and 13C NMR spectra. 
Procedures for antibacterial testing and table of outcomes for individual molecules. 
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